This is a working overview of Angiotensin IV analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-02. Anything still debated is marked as such rather than presented as settled.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
== Career == Working first in the Physical Chemistry Laboratory, he moved to the Dunn Nutritional Laboratory, and in 1938 moved to Wool Industries Research Institution in Leeds. He was head of the biochemistry division of Boots Pure Drug Company from 1946 to 1948, when he joined the Medical Research Council. There, he was appointed head of the physical chemistry division of the National Institute for Medical Research in 1952, and was chemical consultant from 1956 to 1959. He specialised in biochemistry, in some aspects of vitamins E and B2, and in techniques that laid the foundation for several new types of chromatography. He developed partition chromatography whilst working on the separation of amino acids, and later developed gas-liquid chromatography with Anthony T. James. Amongst many honours, he received his Nobel Prize in 1952. After his retirement from the University of Sussex, he was visiting professor at both the University of Houston in Texas and the EPFL (École Polytechnique Fédérale de Lausanne) in Switzerland. He published far fewer papers than the typical Nobel winners—only 70 in all—but his ninth paper contained the work that would eventually win him the Nobel Prize. The University of Houston dropped him from its chemistry faculty in 1979 (when he was 69 years old) because he was not publishing enough.
Probable migraine describes conditions that have some characteristics of migraine, but where there is not enough evidence to diagnose it as migraine with certainty. Menstrual migraines are those that either only occur associated with a menstrual period, or occur predictably around menstrual period alongside migraines during other parts of the menstrual cycle. They typically occur in migraines without aura. They are often longer than other migraine attacks, and associated with more nausea.
Asymptomatic HS (mild): 20–30% of patients. Infantile-onset HS (moderate): 60–75% of patients. Neonatal or in-utero onset HS (severe): <5% of patients. The most common presentation will demonstrate jaundice (due to increased unconjugated bilirubin), anemia (with secondary pallor) and a palpable spleen, sometimes with concomitant tenderness (due to splenic congestion and splenomegaly). It is worth noting that a subsection of HS patients will also have incidental black pigmented gallstones made of calcium bilirubinate (a consequence of the extravascular hemolysis), and some of these patients will develop cholelithiasis or the potential complex sequelae of this condition (e.g. cholecystitis, choledocholithiasis, etc.).
Sources: en.wikipedia.org
=== The New York Times === On April 2, 2023, the main account for The New York Times became one of the first major media companies to lose its verified status on Twitter. Ahead of the official release of Verification for Organizations, newspaper The New York Times stated that it would not pay for a verification checkmark. In response to a Twitter user who pointed out the newspaper's decision, Musk stated, "Oh ok, we'll take it off then". Musk then called The New York Times hypocritical for charging readers to read its articles. He criticised the newspaper for tweeting hundreds of posts every day, including drafts that were not accepted into the published editions of the paper, and inundating the daily feed of users who followed it. Despite the deadline for Twitter Blue passing, and aside from The New York Times, many legacy verified accounts continued to retain their verified status. According to The New York Times themselves, the top 10,000 Twitter accounts and top 500 advertisers would be exempt from paying.
In April 2019, Rolling Stone ranked the album at No. 6 on its list of the "50 Greatest Grunge Albums". In 2024, Loudwire staff elected it as the best hard rock album of 1992. In 2025, Em Casalena of American Songwriter included the album in the site's list of "4 Grunge Albums That Are Way Better Than Nevermind".
2.A: Porters (uniporters, symporters, antiporters), SLCs. Excitatory amino acid transporters (EAATs) EAAT1 EAAT2 EAAT3 EAAT4 EAAT5 Glucose transporter Monoamine transporters, including: Dopamine transporter (DAT) Norepinephrine transporter (NET) Serotonin transporter (SERT) Vesicular monoamine transporters (VMAT) Adenine nucleotide translocator (ANT) 2.B: Nonribosomally synthesized porters, such as: The Nigericin family The Ionomycin family 2.C: Ion-gradient-driven energizers
The decay of radon-222 was once reported to exhibit large 4% peak-to-peak seasonal variations (see plot), which were proposed to be related to either solar flare activity or the distance from the Sun, but detailed analysis of the experiment's design flaws, along with comparisons to other, much more stringent and systematically controlled, experiments refute this claim.
Sources: en.wikipedia.org
A new Media Act was passed into law in 1967, merging the NRU and the NTS. The new organisation, the Nederlandse Omroep Stichting (Netherlands Broadcasting Service; NOS) was created on 29 May 1969. The NOS, as were its predecessors, was tasked with coordinating the whole public broadcasting system, as well as providing news and sports bulletins. It also inherited the technical and production facilities needed to make and broadcast radio and television programmes. All broadcasting members of the NRU and the NTS were made members of the NOS. By 1971 seven programming societies existed, each receiving part of the television licence fee and advertising revenue. Because of pillarization most represented various political and religious groups, although the largest, AVRO, was the most neutral. Twenty-seven smaller groups such as the Society for Sexual Reform received small time slots, as well as all parties represented in the Dutch Parliament. Societies produced their own programs, and purchased others from abroad. Besides news and sports, NOS produced children and educational programs for the one third of broadcast hours it filled. On 2 May 1977, a strike by sound engineers affected television news broadcasts. Upset viewers called on all broadcasters to resolve the situation. On 1 April 1980, the NOS launched its teletext service, in the framework of supplying news and information. It first experimented with Teletext in 1977. In 1981, on the 25th anniversary, the NOS aired its first televised youth news bulletin, called Jeugdjournaal.
A simple staining method for bacteria that is usually successful, even when the positive staining methods fail, is to use a negative stain. This can be achieved by smearing the sample onto the slide and then applying nigrosin (a black synthetic dye) or India ink (an aqueous suspension of carbon particles). After drying, the microorganisms may be viewed in bright field microscopy as lighter inclusions well-contrasted against the dark environment surrounding them. Negative staining is able to stain the background instead of the organisms because the cell wall of microorganisms typically has a negative charge which repels the negatively charged stain. The dyes used in negative staining are acidic. Note: negative staining is a mild technique that may not destroy the microorganisms, and is therefore unsuitable for studying pathogens.
== History == The deficiency was the first metabolic myopathy to be recognized when the physician Brian McArdle described the first case in a 30-year-old man who always experienced pain and weakness after exercise. McArdle noticed this patient's cramps were electrically silent and his venous lactate levels failed to increase upon ischemic exercise. (The ischemic exercise consists of the patient squeezing a hand dynamometer at maximal strength for a specific period, usually a minute, with a blood pressure cuff, which is placed on the upper arm and set at 250 mmHg, blocking blood flow to the exercising arm.) Notably, this is the same phenomenon that occurs when muscle is poisoned in vitro by iodoacetate, which inhibits the breakdown of glycogen into glucose and prevents the formation of lactate; as well as produces an electronically silent muscle contracture. Knowing what occurs to muscle poisoned by iodoacetate, helped McArdle speculate that a glycogenolytic block might be occurring when he first described the disease. McArdle accurately concluded that the patient had a disorder of glycogen breakdown that specifically affected skeletal muscle. The associated enzyme deficiency was discovered in 1959 by W. F. H. M. Mommaerts et al.
=== Campaign history === 2012 US Senate election: 2,249 votes (0.07%) 2009 Gubernatorial election: 2,085 votes (0.09%) 2006 US Senate election: 2,490 votes (0.1%) 2002 US Senate election: 2,702 votes (0.13%) 2000 US Senate election: 3,365 votes (0.11%) 1997 Gubernatorial election: 2,800 votes (0.12%) 1994, District 9 Congressional election: 1,490 votes (0.93%)
== Research == Townsend's research has combined advanced proteomics and drug metabolism with biochemistry to identify molecular targets affected by oxidative and nitrosative stress. Her lab has focused on understanding the events leading to the endoplasmic reticulum (ER) stress response, specifically examining stress-induced impacts on proteins involved in protein folding. Her publication record includes an H-index of over 50, with more than 13,000 citations.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.